Biotechnology Industry · eu
BioNTech Prepares for Founder Handover: Sobi CEO Oelkers to Take the Helm at a Critical Stage for Drug Launches
As BioNTech shifts from the global prominence of its COVID-19 vaccine toward the clinical and commercial delivery of cancer drugs, it is bringing in rare-disease pharmaceutical veteran Guido Oelkers to steer its goal of becoming a multi-product company by 2030.
BioNTech is arranging a founder handover at the most demanding stage of the company’s transformation. The German biotechnology company, widely known for its mRNA vaccine, announced that Guido Oelkers, the current CEO of Swedish rare-disease drugmaker Sobi, will join its Management Board and succeed co-founder Uğur Şahin as CEO no later than February 2027.
Şahin has been the scientific and business leader at the heart of BioNTech since founding the company in 2008. The leadership arrangement follows the transformation plan previously announced by BioNTech: Şahin and co-founder Özlem Türeci will leave their current management roles and establish a separate company to develop next-generation mRNA technologies, while the original company’s clinical assets and commercialization responsibilities will be advanced by a new leadership team.
Oelkers has led Sobi since 2017, with a career spanning pharmaceuticals, medical devices, and global commercial operations. For BioNTech, the appointment indicates that the board now needs more than scientific vision; it also needs expertise in product launches, market access across countries, and organizational expansion—capabilities that will directly affect whether drug candidates can complete the final stretch from late-stage trials to actual sales.
BioNTech aims to become a biopharmaceutical company with multiple approved products by 2030, focusing on antibody-drug conjugates, bispecific immunomodulators, and cancer vaccines. This portfolio is more diverse than a single mRNA platform and brings more complex trial design, manufacturing, regulatory, and commercial planning. The new CEO’s first challenge will be to prioritize resources across the different technology platforms.
The transition is therefore more than a change in senior leadership. It also marks BioNTech’s further shift from a founder-led research and development enterprise toward an institutionalized, multi-product commercial company. The COVID-19 vaccine provided funding and global infrastructure, but whether its cancer drugs can replicate the same level of success will still depend on late-stage clinical data, regulatory review, and whether they demonstrate sufficient benefits compared with existing therapies.
The news currently comes mainly from BioNTech’s corporate announcement, with little independent reporting available to supplement it. The appointment itself also cannot answer which drug candidates will be approved first or whether the 2030 goal can be achieved on schedule. The real test of this handover will be the results of pivotal trials and the progress of product launches over the next several years.